Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 563

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

Open access
Bywater, Megan J., Poortinga, Gretchen, Sanij, Elaine, Hein, Nadine, Peck, Abigail, Cullinane, Carleen, Wall, Meaghan, Cluse, Leonie, Drygin, Denis, Anderes, Kenna, Huser, Nanni, Proffitt, Chris, Bliesath, Joshua, Haddach, Mustapha, Schwaebe, Michael K., Ryckman, David M., Rice, William G., Schmitt, Clemens, Lowe, Scott W., Johnstone, Ricky W., Pearson, Richard B., McArthur, Grant A., Hannan, Ross D.·2012·Cancer Cell

Abstract

Increased transcription of ribosomal RNA genes (rDNA) by RNA Polymerase I is a common feature of human cancer, but whether it is required for the malignant phenotype remains unclear. We show that rDNA transcription can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells in vivo while maintaining a viable wild-type B cell population. The therapeutic effect is a consequence of nucleolar disruption and activation of p53-dependent apoptotic signaling. Human leukemia and lymphoma cell lines also show high sensitivity to inhibition of rDNA transcription that is dependent on p53 mutational status. These results identify selective inhibition of rDNA transcription as a therapeutic strategy for the cancer specific activation of p53 and treatment of hematologic malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2012.05.019

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 563

Metadata

Authors
Bywater, M. J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., Wall, M., Cluse, L., Drygin, D., Anderes, K., Huser, N., Proffitt, C., Bliesath, J., Haddach, M., Schwaebe, M. K., Ryckman, D. M., Rice, W. G., Schmitt, C., Lowe, S. W., Johnstone, R. W., Pearson, R. B., McArthur, G. A., & Hannan, R. D.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2012-07
Volume
22
Issue
1
Pages
51-65
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2129104457
Cited by
563
References
4
FWCI
16.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. https://app.cochat.ai/papers/10.1016/j.ccr.2012.05.019
The paper
Bywater, M. J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., Wall, M., Cluse, L., Drygin, D., Anderes, K., Huser, N., Proffitt, C., Bliesath, J., Haddach, M., Schwaebe, M. K., Ryckman, D. M., Rice, W. G., Schmitt, C., Lowe, S. W., . . . Hannan, R. D. (2012). Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. Cancer Cell. https://doi.org/10.1016/j.ccr.2012.05.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.